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A signiﬁcant proportion of patients with chronic hepatitis C virus (HCV) infection develop liver cirrhosis and complications
of end-stage liver disease over two to three decades and require liver transplantation, however , reinfection is common and
leads to further adverse events under immunosuppression. Pretransplant antiviral or preemptive therapy is limited to mildly
decompensated patients due to poor tolerance. The mainstay of management represents directed antiviral therapy after evidence
of recurrence of chronic hepatitis C. Combined pegylated interferon and ribavirin therapy is the current standard treatment with
sustained viral response rates of 25% to 45%. The rate is lower than that in the immunocompetent population, partly due to
the high prevalence of intolerability. To date, there is no general consensus regarding the antiviral treatment modality, timing,
or dosing for HCV in patients with advanced liver disease and after liver transplantation. New anti-HCV drugs to delay disease
progression or to enhance viral clearance are necessary.
1.Introduction
According to the World Health Organization, 130 to 170
million people are chronically infected with hepatitis C virus
(HCV) and 3 to 4 million people are newly infected each
year worldwide [1]. The median time to develop cirrhosis
is estimated to be 30 years, and 33% of patients have an
expected median time to the development of cirrhosis of
less than 20 years. Although antiviral therapy is available,
the number of patients with end-stage liver disease due to
HCV will continue rise over the next 10 years [2]. HCV is
the major cause of chronic liver disease, cirrhosis, and liver
cancer in most developed countries [3], including Japan [4].
It is the most common indication for liver transplantation in
developed nations [5, 6].
Liver transplantation is an eﬀective treatment to reduce
morbidity and mortality in this population. Reinfection with
HCV, however, is a critical complication with major eﬀects
on graft and patient survival. Indeed, the real challenge of
controllingHCVbeginsafterlivertransplantationunderlife-
long immunosuppression, and mitigating the damage is a
crucial concern. In this paper, we focus on this challenging
aspect, evaluating the available treatment options and strate-
gies against HCV before and after transplantation to prevent
reinfection with the goal of eradicating recurrent infection.
2. ClinicalCourseafterLiverTransplantation
Spontaneous clearance of HCV after transplantation is rare
[7–11], and reinfection of the allograft is common [12, 13].
Histologic progression of HCV under immunosuppressive
therapy is more rapid than that in nontransplant patients
[14, 15]. HCV patients have a poorer prognosis after liver
transplantation than those with other indications [16–19],
a ﬁnding that remains unchanged in recent research [20].
Large studies have demonstrated that recipients with HCV
have approximately 10% lower 5-year graft and patient
survival rates than non-HCV controls [18, 19]. One study
comparing approximately 7500 HCV recipients and 20,000
non-HCV recipients reported an overall 3-year patient
survival rate of 79% in HCV patients and 81% in non-
HCVpatients[16].Factorswithasigniﬁcantnegativeimpact2 Hepatitis Research and Treatment
on patient survival include a preoperative model for end-
stage liver disease (MELD) score [21], ﬁbrosis stage of 2 or
greater at 12-month biopsy, advanced donor age, history of
hepatocellular carcinoma (HCC), and early acute rejection
[22].
HCV reinfection occurs during transplantation in the
reperfusionphaseofthegraft,andacutehepatitiscanusually
be detected 1 to 3 months after transplantation [23]. The
clinical course following reinfection varies. In general, 8%
to 30% of the recipients will present with severe progressive
disease within 5 years [15, 17, 24]. The median time to
cirrhosis in the nontransplant patients was 30 years [25]a n d
in the transplanted patients with HCV disease is expected
to be 10 years. The risk of decompensation is 50% within 1
yearafterdiagnosisintheabsenceoftherapeuticintervention
[15,26].Asmallpercentageofrecipientscandevelopanearly
cholestatichepatitiswithintheﬁrstyearaftertransplantation
with a risk (2%–8%) of progressive liver dysfunction and
rapid development of cirrhosis [12, 27]. Retransplantation
in these patients is associated with poor outcomes and is
controversial [28].
3. Risk Factors for Severe Recurrent HCV
The reported risk factors include advanced donor age [29,
30], high viral load in the preoperative or early postoperative
periods [31, 32], treatment of acute rejection [28], long
duration between the antiviral therapy and transplantation
[16, 18, 33], and baseline pre transplant liver function
[34]. The expression of cytokeratin 19 and that of vimentin
in liver biopsies without ﬁbrotic changes (F0) [35]a r e
also considered risk factors for severe recurrent HCV.
Postoperative insulin resistance diabetes mellitus [36, 37],
metabolic syndrome [38], and lipid peroxidation (oxidative
degradation of lipids) [39] are reported to be associated with
severe HCV recurrence.
The role of corticosteroids in severe recurrent HCV
is complicated. Steroid bolus injection as acute rejection
therapy is one of the risk factors for severe HCV recurrence
and graft loss [19]. Rapid withdrawal of corticosteroids
might cause graft ﬁbrosis [40], but a corticoid-free regimen
may be promising [41]. A meta-analysis of randomized trials
using a corticoid-free immunosuppression regimen showed
a signiﬁcant reduction of HCV recurrence in corticoid-free
groups [42].
The impact of other immunosuppressive agents,
including mycophenolate mofetil, azathioprine [43], or
interleukin-2 inhibitors [44] on severe recurrent HCV
remains controversial. OKT3 is associated with increased
graft loss and increased mortality [12].
A viral quasispecies is a group of viruses related by a
similar mutation or mutations, competing within a highly
mutagenic environment. After transplantation, diversiﬁca-
tion of hypervariable region 1 is decreased, and the virus
population becomes more homologous [45] although the
changes might be temporary [46]. A more complex HCV
hypervariable region 1 quasispecies population was reported
to be associated with HCV recurrence after transplantation
[47, 48].
4.ViralKinetics
Powers et al. [49] conﬁrmed that viral loads begin to rise 15
hours after the anhepatic phase. In total, 19% hepatocytes
are infected in an average of 37 days (range: 4–82 days) after
transplantation. Schianoetal.[50] demonstrated accelerated
HCV kinetics in LDLT recipients (n = 11) compared to
deceased donor liver transplantation (DDLT) recipients (n =
15). In their study, HCV RNA levels rose more rapidly in
LDLT patients; the diﬀerences in patient and graft survival,
however, did not reach statistical signiﬁcance.
Another study [51] focusing on the histologic aspects
of HCV recurrence with protocol biopsy reported more
severe progression of HCV disease in LDLT compared
to DDLT. Other studies [52, 53] have also demonstrated
that individuals with a high level of replication in the
perioperative period develop more ﬁbrosis in the allograft 1
year after transplantation. When the graft develops ﬁbrotic
or cirrhotic changes, the patient prognosis is dismal.
5.PretransplantAntiviralTherapy
Antiviral treatment of patients with mildly decompensated
cirrhosis (model for end-stage liver disease, MELD > 18) is a
more problematic approach than treatment after transplan-
tation.
Suitable candidates for pretransplant therapy would
be treatment-na¨ ıve patients or prior relapsers to standard
interferon (IFN) and ribavirin (RBV) treatment because
the chances for an on-treatment virologic response before
transplantation are high [27]. Patients with predictable
timing of transplantation such as those with living donors or
those with HCC may be good candidates for pre-transplant
therapy. The use of growth factors is considered an option
to treat therapy-associated anemia and leucopenia as it
can improve quality of life and may decrease the need for
antiviral therapy dose reduction [54].
Everson et al. [55] reported his experience in the treat-
ment of 102 patients with chronic hepatitis and decompen-
sated liver disease using a low accelerating dosage regimen
of IFN alfa-2b plus RBV. Serum HCV RNA was cleared in
approximately 40% of patients on this treatment, and 22%
achieved a sustained virologic response (SVR).
F o r n se ta l .[ 56] administered antiviral therapy to
patients with IFN alpha-2b 3MU/day and RBV 800mg/day
when the expected time until transplantation was less than 4
months.Of30patientsenrolled,9(30%)achievedavirologic
response and 21 did not respond to therapy. Of the nine,
six remained free of infection after a median followup of
46 weeks and HCV infection recurred in three patients after
transplantation. In contrast, Smallwood et al. [57]r e p o r t e d
that patients treated with IFN before transplantation have a
signiﬁcantly earlier and more aggressive recurrence of HCV.
Carri´ on et al.[58] performed a case control study comparing
51 patients who underwent treatment with IFN and RBV
and a control group (untreated 51 individuals awaiting
transplantation who were matched by age, Child-Pugh, and
time on the waiting list). There was a higher incidence of
bacterial infections after transplantation in treated patients,Hepatitis Research and Treatment 3
particularly in Child-Pugh B-C individuals. Further data are
needed before a deﬁnitive conclusion can be drawn.
6.EarlyPosttransplant Antiviral
(Preemptive) Therapy
6.1. Its Rationale and Use in LDLT Patients. Preemptive
treatment may be beneﬁcial in potentially tolerant patients,
suchaspatientswithalowernaturalMELDscoreundergoing
liver transplantation for HCC within the Milan criteria, with
an outcome comparable to that of non-HCC cases, and also
in well-planned LDLT cases [59] with splenectomy [60].
The preemptive approach may provide an oncologic beneﬁt,
which has been demonstrated in nontransplant patients with
HCV who underwent liver resection for HCC [61].
The rationale for preemptive therapy is to strike at
a time when the total HCV viral load is relatively low
after liver transplantation [23, 49] and histologic damage
is absent or minimal. Delay of histologic damage can be
expected [62, 63]. Garcia-Retortillo et al. [23]o b s e r v e da
rapid decrease in the viral load during the anhepatic phase
in 20 patients who underwent liver transplantation for HCV.
The viral load continued to exponentially decrease after graft
reperfusion with a progressive increase after the ﬁrst week
of transplantation, reaching a plateau by the end of the ﬁrst
month.
We examined the feasibility and eﬃcacy of a preemptive
combination of IFN and RBV therapy against HCV in LDLT
patients [64]. Tolerance was a limiting factor, with 25% of
the patients deviating from the planned protocol. Overall,
among the 23 patients enrolled, 9 (39%) achieved SVR.
The cumulative 3-year survival rate did not diﬀer between
the enrolled patients and the HCV-negative patients (90%)
during the study period [59]. The results of the study
were encouraging and demonstrated an optimal window for
treatment initiation and the optimal doses of IFN and RBV
necessary for eﬀective viral eradication [65]a f t e rL D L T .
6.2. In DDLT. The overall eﬃcacy and feasibility of pre-
emptive therapy in DDLT is controversial. Randomized
studies on a preemptive approach with IFN monotherapy
[66, 67] or combined therapy [63] demonstrated a reduced
or delayed incidence of hepatitis after liver transplantation,
but not the prevention of viremia. Discontinuation of the
treatment was necessary in 30% of the subjects in the study.
Mazzaferro et al. [68] treated 36 recipients with IFN-alpha-
2b(3 million IU, 3 times/week) and RBV(10mg/kg perday).
The treatment was initiated at a median of 18 days after the
operation and continued for a year. After a median followup
of 52 months, 5-year patient survival was 88%. Serum
HCV RNA was cleared in 12 patients of the 36 recipients
(33%) after a median of 37 days. These patients remained
negative for serum HCV RNA for a median of 36 additional
months without antiviral treatment. Dose reduction was
necessaryin9(25%)patients.Althoughtheseoutcomeswere
encouraging, the current understanding is that the adverse
events associated with treatment outweigh the theoretical
beneﬁts of preemptive therapy [12].
Shergill et al. [69] reported about the results of preemp-
tive treatment. Only 51 (41%) of 124 transplant recipients
were eligible for preemptive treatment; eligible patients had
lower MELD and Child-Pugh scores pretransplantation.
Dose reductions and discontinuations were required in 85%
and 37% of patients, respectively, and 27% experienced
serious adverse events. Only 15% of patients were able
to achieve full-dose treatment during treatment. End-of-
treatment rate and SVR were 14% and 9%, respectively.
7. Treatment for Established Infection
The recommendation of the International Liver Transplan-
tation Society is to perform post-transplant surveillance and
protocol biopsies to detect recurrent HCV disease [70]a n d
to start combined pegylated-(peg-) IFN and RBVtherapy for
stage II ﬁbrosis [12]. Treatment of HCV recurrence is mostly
modeled after the strategy of treating HCV in nontransplant
patients [5, 6]: Studies of a noncontrolled series of patients
[71–81]r e v e a l e da ne ﬃcacy of 26% to 50% after peg-IFN
and RBV therapy, a higher eﬃcacy than that of conventional
IFN and RBV therapy.
These studies suggested that factors associated with
higher probabilities of a viral response were nongenotype
1, low pretreatment HCV RNA levels, absence of advanced
cirrhosis, early virologic response (≥ 2 log drop in HCV
RNA from baseline at 3 months), and adherence to combi-
nation therapy [71, 82–93] similar to that in nontransplant
patients. Other reports [90, 94] suggested that patients
on cyclosporine had a higher SVR. Berenguer et al. [73]
reported a higher SVR rate for nongenotype 1 (60%) versus
genotype 1 (31%) and a higher SVR rate with peg-IFN
with RBV compared to standard IFN with RBV (50% versus
13%). Combined treatment with peg-IFN is suggested to be
eﬀective among those who failed previous conventional IFN
and RBV therapy, achieving an SVR in 30% with histologic
improvement [95]. These studies were, however, limited by
small sample sizes and a lack of randomized controlled trials.
Carri´ on et al. [96] studied patients with mild HCV
recurrence (ﬁbrosis stage F0-2) that were randomized into
two groups; group A, no treatment; group B, treated
withcombinedpeg-IFN-alpha-2b(1.5μg/kg/week)andRBV
(adjusted for renal function, maximum dose 1200mg/day)
for 48 weeks. Median time to treatment was 14 months. An
SVR was achieved in 0 (0%) and 13 (48%), respectively. His-
tologic stabilization or improvement, which corresponded
with improvement in the hepatic venous pressure gradient,
was recognized with an SVR. Early virologic response was an
independentsigniﬁcantfactorpredictingSVRinthestudy,as
described previously [97–99]. Dose reduction was necessary
in 67% of cases, and interruption was necessary in 56%.
An increased risk of rejection in the treatment groups was
not substantiated. The study demonstrated the advantage of
antiviral treatment with peg-IFN and RBV, which achieves
permanent viral clearance in a high proportion of patients
when initiated at the stage of mild HCV recurrence.
One systematic review [100] of the eﬃcacy of post-
transplant treatment with standard IFN (IFN-RBV) [93,
101–117] or peg-IFN in combination with RBV (peg-RBV)4 Hepatitis Research and Treatment
[77–80, 118–120] given for 6 to 12 months included 38
studies. Patients were predominantly men with a high rate of
genotype 1 infection (> 80%). IFN-RBV was associated with
an end-of-treatment virologic response rate of 34% and an
SVR rate of 24%, while peg-RBV was associated with an end-
of-treatment virologic response rate of 42% and an SVR rate
of 27%. Pooled discontinuation rates were 24% with IFN-
RBV and 26% with peg-RBV. Only 33% with IFN-RBV and
21% with peg-RBV completed the intended protocol. The
majorityofpatientsrequireddosereduction.Theoverallrate
of acute graft rejection was 2% with IFN-RBV and 5% with
peg-RBV. The authors concluded that combination therapies
have similar tolerability and safety, but the advantage of peg-
RBV in terms of viral response remains unclear, and further
studies are required.
A n o t h e rs y s t e m a t i cr e v i e w[ 121] focused only on studies
using peg-IFN in combination with RBV as post-transplant
treatment. The 19 reviewed studies showed a mean end-
of-treatment response of 42% and a mean overall SVR of
30%. A recent study [122] disclosed an SVR rate of 64% in
DDLT patients. The antiviral treatment regimen comprised
pegylated-IFN (180μg) every 2 weeks and RBV at a dose of
200 to 400mg every day. The treatment duration was ﬂexible
and individualized, and it depended on the viral response to
treatment.Thedosageoftacrolimuswasdecreasedgradually.
8. Nonresponders
When an SVR cannot be achieved, the next possible best
step is to prevent the progression of ﬁbrosis. Peg-IFN may be
histologically beneﬁcial even when HCV eradication is not
obtained [123, 124]. Studies of nonresponders to determine
the optimal dosage and duration of either IFN, RBV, or
both are lacking in terms of delayed disease progression.
Administration of oral ursodeoxycholic acid may be bene-
ﬁcial in terms of improving the biochemical response, but
not histologic changes, as recently demonstrated in a large-
scale, multicenter, double-blind trial in a nontransplant
population [125]. It has no clear beneﬁts in liver transplant
recipients [126].
In a subset of patients with a progressive cholestatic
variantofHCVdisease[127]despitecombinedIFNandRBV
therapy,indeﬁnitecontinuationofantiviraltherapy[128],or
temporary treatment with double-ﬁltration plasmapheresis
[129, 130], a novel option to decrease HCV viral load, in
combination with antiviral therapy may be eﬀective [130].
Further studies focusing on the long-term risks and beneﬁts
ofvarioustreatmentmodalitiesforpatientsnonresponsiveto
antiviral therapy are necessary.
9.FuturePerspectives
Previous descriptions [131] as well as the descriptions above
indicate the need for additional treatment modalities. The
treatment goal should be eventual viral eradication. In
theory, this goal can be achieved by disrupting the steady-
state HCV kinetics by reducing virion production, thereby
allowing infected cells to be eliminated [132, 133]. Lang
[134]classiﬁesthefuturedrugscurrentlyunderinvestigation
into four categories: new IFNs, RBV alternatives, speciﬁc
HCV inhibitors, and immunomodulators. Some of these
drugs are in phase III trials awaiting further clinical evalu-
ation.
As tolerability is the primary problem of the current
widely applied combined IFN and RBV treatment after liver
transplantation,speciﬁcHCVlife-cycleinhibitorsmayhavea
beneﬁcialrole.Amongthevariousdrugsunderinvestigation,
protease inhibitors such as telaprevir and boceprevir appear
to be safe and are currently undergoing clinical evaluation. A
clinical trial with triple combinations of peg-IFN, RBV, and
telaprevir has been performed [135] in patients with chronic
HCV.TheSVRsofthepatientsadministeredtelaprevirfor24
and48weekswere61% and67%, respectively.HighSVR was
obtained in patients who had not had a sustained response
to the therapy with peg-IFN and RBV [136]. The SVR of the
control patients (peg-IFN and RBV for 48 weeks) was 41%.
A phase-III clinical trial of boceprevir was begun in 2008
[137–140]. None of the new anti-HCV drugs, however, are
currently being evaluated in HCV-infected liver transplant
recipients.
10. Conclusions
HCV continues to be a major challenge in liver trans-
plantation. Reinfection is common after transplantation,
and progression of the disease leads to a dismal outcome.
Pretransplant antiviral therapy with at least on-treatment
virologic response at the time of transplantation would be
desirable, but the tolerability and risk of therapy limits
the applicability to patients with compensated or mildly
decompensated liver disease (low MELD score). Preemptive
treatment is also limited by frequent complications in the
earlypost-transplantphaseandahighrateofsideeﬀects.The
use of combined peg-IFN and RBV therapy has increased the
rate of viral clearance, but its intolerability in the majority
of patients prevents its general application. The overall risk
andbeneﬁtofthecurrentstrategyoverthelongtermremains
tobeevaluated. Additional modalities combining newdrugs,
such as protease inhibitors, should be pursued.
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